ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine
- PMID: 39837579
- DOI: 10.1136/rapm-2024-105651
ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine
Abstract
Background: To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management.
Methods: Following board approval, in 2020 the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) commissioned evidence-based guidelines for best practices for infection control. More than 80 research questions were developed and literature searches undertaken by assigned working groups comprising four to five members. Modified US Preventive Services Task Force criteria were used to determine levels of evidence and certainty. Using a modified Delphi method, >50% agreement was needed to accept a recommendation for author review, and >75% agreement for a recommendation to be accepted. The ASRA Pain Medicine Board of Directors reviewed and approved the final guidelines.
Results: After documenting the incidence and infectious complications associated with regional anesthesia and interventional pain procedures including implanted devices, we made recommendations regarding the role of the anesthesiologist and pain physician in infection control, preoperative patient risk factors and management, sterile technique, equipment use and maintenance, healthcare setting (office, hospital, operating room), surgical technique, postoperative risk reduction, and infection symptoms, diagnosis, and treatment. Consensus recommendations were based on risks associated with different settings and procedures, and keeping in mind each patient's unique characteristics.
Conclusions: The recommendations are intended to be multidisciplinary guidelines for clinical care and clinical decision-making in the regional anesthesia and chronic interventional pain practice. The issues addressed are constantly evolving, therefore, consistent updating will be required.
Keywords: analgesics, opioid; injections, spinal; nerve block; pain management; spinal cord stimulation.
© American Society of Regional Anesthesia & Pain Medicine 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: HTB, TLD, RLJ, HK, SLK, SN, ACSP, ES, and JVZ have no competing interests. KC: existing relationship with BD via contract for providing educational content on sepsis as a lecturer and participating in a sepsis advisory committee meeting. JSG: shareholder in startup company at UK Intralink sine, which was purchased by Spinal Simplicity but has no product on the market. MH: consults for Abbott and Medtronic. BH: consultant for Nevro and Boston Scientific. CH: principal investigator for research grant paid to institution from Nevro for investigator-initiated research study to support research coordinator efforts. Research agreement with Abbott, paid to institution (I am not the principal investigator but am involved with the 51 research.). SH: consultant/advisor for B. Baun and Shiratronics. RL: has received research funding from Sage Medical, B. Braun, Draeger, Surfacide, and Kenall, has one or more patents pending, and is a partner of RDB Bioinformatics, the company that owns OR PathTrac. He receives no funds personally from his involvement in RDB. He has spoken at educational meetings sponsored by Kenall and B. Braun. AJRM: consulting fees from Intelligent Ultrasound; honorarium for teaching from GE Healthcare. AN: Saol Therapeutics–research funds provided to my institution for research that I perform. SN: consults for Shiratronics and is a member of the Boards of Directors for the ASRA Pain Medicine and American Interventional Headache Society (AIHS). AP: paid honoraria from GE Healthcare for teaching, consultancy for Pacira Pharmaceuticals. JP: grant support from Medtronic, Boston Scientific, Abbott, NIH 2R01CA166379, NIH R01EB030324, and NIH U44NS115111. Medical advisor for Aim Medical Robotics and has stock equity. DAP: has consulted for Avanos, Boston Scientific, Medtronic, Nevro, and SI Bone. Pain Diagnostics and Interventional Care has received research support from Avanos, Boston Scientific, Medtronic, Nevro, Stimgenics, and Abbott. DAP serves on the Board of ASRA Pain Medicine. RVS: consultation fees from CIVCO.
LinkOut - more resources
Full Text Sources